약물 용출 스텐트 시장 보고서 : 코팅, 약제, 스텐트 플랫폼, 세대, 용도, 최종 사용자, 지역별(2025-2033년)

The global drug-eluting stents market size reached USD 8.8 Billion in 2024. Looking forward, the market is expected to reach USD 14.2 Billion by 2033, exhibiting a growth rate (CAGR) of 5.23% during 2025-2033. The increasing prevalence of cardiovascular diseases is propelling the market.

A drug-eluting stent (DES) is a coronary device that is used for the slow release of drugs in peripheral or coronary arteries to block cell proliferation and promote a healthy flow of blood. It consists of a metallic stent, polymer coating and anti-restenosis drug. The stent is coated with medications that assist the arteries to remain smooth and ensure adequate blood flow. DES is widely used to treat blockages in heart arteries, prevent plaque buildup, blood clots and reduce repeated revascularization. The stent is minimally invasive (MI) and offers lower restenosis rates, enhanced vessel healing and reduced need for prolonged dual antiplatelet therapy.

Drug-Eluting Stents Market Trends:

The rising geriatric population prone to chronic medical ailments is one of the key factors driving the growth of the market. DES is widely utilized in patients with a high risk of developing arterial disorders as the stents aid in reducing the need for invasive procedures, such as coronary artery bypass surgeries. Additionally, the increasing prevalence of cardiovascular diseases due to the unhealthy dietary patterns, lack of physical activity and sedentary lifestyles of the masses is favoring the market growth. Moreover, various technological advancements, such as the launch of bioresorbable stents, are providing a thrust to the market growth. These stents are easily dissolvable in the body and reduce the risk of developing stent thrombosis. In line with this, the widespread adoption of stents with polymer-free coatings is positively impacting the market growth. These stents exhibit a higher drug loading capacity and quicker drug-eluting rate. Other factors, including the rising incidence of abnormal heart rhythms, heart failure and heart attack disease, along with the increasing demand for MI techniques among the masses, are anticipated to drive the market toward growth.

Global Drug-Eluting Stents Industry Segmentation:

Breakup by Coating:

Polymer Based Coating

Polymer Free Coating

Breakup by Drug:

Sirolimus

Paclitaxel

Zotarolimus

Everolimus

Biolimus

Others

Breakup by Stent Platform:

Stainless-steel

Cobalt-Chromium

Platinum-Chromium

Nitinol

Others

Breakup by Generation:

1st Generation

2nd Generation

3rd Generation

4th Generation

Breakup by Application:

Coronary Artery Disease

Peripheral Artery Disease

Breakup by End User:

Hospitals

Ambulatory Surgical Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun Melsungen AG, Biosensors International Group Ltd., Biotronik, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC (Cook Group Incorporated), Lepu Medical Technology (Beijing) Co. Ltd., Medtronic plc, MicroPort Scientific Corporation, Sino Medical Sciences Technology Inc. and Terumo Corporation.

Key Questions Answered in This Report

• 1. What was the size of the global drug-eluting stents market in 2024?
• 2. What is the expected growth rate of the global drug-eluting stents market during 2025-2033?
• 3. What are the key factors driving the global drug-eluting stents market?
• 4. What has been the impact of COVID-19 on the global drug-eluting stents market?
• 5. What is the breakup of the global drug-eluting stents market based on the coating?
• 6. What is the breakup of the global drug-eluting stents market based on the stent platform?
• 7. What is the breakup of the global drug-eluting stents market based on application?
• 8. What is the breakup of the global drug-eluting stents market based on the end user?
• 9. What are the key regions in the global drug-eluting stents market?
• 10. Who are the key players/companies in the global drug-eluting stents market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Drug-Eluting Stents Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Coating

• 6.1 Polymer Based Coating
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Polymer Free Coating
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Drug

• 7.1 Sirolimus
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Paclitaxel
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Zotarolimus
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Everolimus
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Biolimus
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Stent Platform

• 8.1 Stainless-steel
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cobalt-Chromium
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Platinum-Chromium
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Nitinol
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Generation

• 9.1 1st Generation
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 2nd Generation
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 3rd Generation
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 4th Generation
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Application

• 10.1 Coronary Artery Disease
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Peripheral Artery Disease
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast

11 Market Breakup by End User

• 11.1 Hospitals
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Ambulatory Surgical Centers
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia-Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 SWOT Analysis

• 13.1 Overview
• 13.2 Strengths
• 13.3 Weaknesses
• 13.4 Opportunities
• 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 Abbott Laboratories
    • 17.3.1.1 Company Overview
    • 17.3.1.2 Product Portfolio
    • 17.3.1.3 Financials
    • 17.3.1.4 SWOT Analysis
  • 17.3.2 B. Braun Melsungen AG
    • 17.3.2.1 Company Overview
    • 17.3.2.2 Product Portfolio
    • 17.3.2.3 SWOT Analysis
  • 17.3.3 Biosensors International Group Ltd.
    • 17.3.3.1 Company Overview
    • 17.3.3.2 Product Portfolio
  • 17.3.4 Biotronik
    • 17.3.4.1 Company Overview
    • 17.3.4.2 Product Portfolio
    • 17.3.4.3 SWOT Analysis
  • 17.3.5 Boston Scientific Corporation
    • 17.3.5.1 Company Overview
    • 17.3.5.2 Product Portfolio
    • 17.3.5.3 Financials
    • 17.3.5.4 SWOT Analysis
  • 17.3.6 Cardinal Health Inc.
    • 17.3.6.1 Company Overview
    • 17.3.6.2 Product Portfolio
    • 17.3.6.3 Financials
    • 17.3.6.4 SWOT Analysis
  • 17.3.7 Cook Medical LLC (Cook Group Incorporated)
    • 17.3.7.1 Company Overview
    • 17.3.7.2 Product Portfolio
    • 17.3.7.3 SWOT Analysis
  • 17.3.8 Lepu Medical Technology (Beijing) Co. Ltd.
    • 17.3.8.1 Company Overview
    • 17.3.8.2 Product Portfolio
    • 17.3.8.3 Financials
  • 17.3.9 Medtronic plc
    • 17.3.9.1 Company Overview
    • 17.3.9.2 Product Portfolio
    • 17.3.9.3 Financials
    • 17.3.9.4 SWOT Analysis
  • 17.3.10 MicroPort Scientific Corporation
    • 17.3.10.1 Company Overview
    • 17.3.10.2 Product Portfolio
  • 17.3.11 Sino Medical Sciences Technology Inc.
    • 17.3.11.1 Company Overview
    • 17.3.11.2 Product Portfolio
  • 17.3.12 Terumo Corporation
    • 17.3.12.1 Company Overview
    • 17.3.12.2 Product Portfolio
    • 17.3.12.3 Financials
    • 17.3.12.4 SWOT Analysis